Drugs / ASTED
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT02393183 | Jul 2019 → Jun 2022 | disease of orbital part of eye adnexa | Iran University of Medical Sciences | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASTED | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02393183 ↗ |
| Route | Oral | “A tablet of ASTED will be taken twice a day” NCT02393183 ↗ |